Human immunodeficiency virus type 1 viral protein R (Vpr) induces CCL5 expression in astrocytes via PI3K and MAPK signaling pathways

Mohitkumar R Gangwani1, Richard J Noel Jr2, Ankit Shah1, Vanessa Rivera-Amill3 and Anil Kumar1*

Abstract

Background: Neurocognitive impairments remain prevalent in HIV-1 infected individuals despite current antiretroviral therapies. It is increasingly becoming evident that astrocytes play a critical role in HIV-1 neuropathogenesis through the production of proinflammatory cytokines/chemokines. HIV-1 viral protein R (Vpr) plays an important role in neuronal dysfunction; however, its role in neuroinflammation is not well characterized. The major objective of this study was to determine the effect of Vpr in induction of proinflammatory chemokine CCL5 in astrocytes and to define the underlying mechanism(s).

Methods: SVGA astrocytes were either mock transfected or were transfected with a plasmid encoding HIV-1 Vpr, and the cells were harvested at different time intervals. The mRNA level of CCL5 expression was quantified using real-time RT-PCR, and cell culture supernatants were assayed for CCL5 protein concentration. Immunocytochemistry was performed on HIV-1 Vpr transfected astrocytes to check CCL5 expression. Various signaling mechanisms such as p38 MAPK, PI3K/Akt, NF-κB and AP-1 were explored using specific chemical inhibitors and siRNAs.

Results: HIV-1 Vpr transfected astrocytes exhibited time-dependent induction of CCL5 as compared to mock-transfected astrocytes at both the mRNA and protein level. Immunostained images of astrocytes transfected with HIV-1 Vpr also showed much higher accumulation of CCL5 in comparison to untransfected and mock-transfected astrocytes. Pre-treatment with NF-κB (SC514) and PI3K/Akt (LY294002) inhibitor partially abrogated CCL5 mRNA and protein expression levels as opposed to untreated controls after HIV-1 Vpr transfection. Specific siRNAs against p50 and p65 subunits of NF-κB, p38 MAPK, Akt-2 and Akt-3, and AP-1 transcription factor substantially inhibited the production of CCL5 in HIV-1 Vpr transfected astrocytes.

Conclusion: These results demonstrate the ability of HIV-1 Vpr to induce CCL5 in astrocytes in a time-dependent manner. Furthermore, this effect was observed to be mediated by transcription factors NF-κB and AP-1 and involved the p38-MAPK and PI3K/Akt pathway.

Keywords: HIV-1, Vpr, CCL5, NF-κB, AP-1, MAPK, PI3K/Akt

* Correspondence: kumaran@umkc.edu
1Division of Pharmacology and Toxicology, School of Pharmacy, University of Missouri, Kansas City, MO 64108, USA
Full list of author information is available at the end of the article

© 2013 Gangwani et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction
HIV-1 enters the central nervous system (CNS) very early in the course of the disease and causes productive infection in the perivascular macrophages and microglia of the brain [1-3]. HIV-associated neurocognitive disorders or HAND is a common complication of nervous system with HIV-1 infection and is comprised of cognitive, motor and behavioral symptoms. The milder form of neurocognitive impairment, minor cognitive motor disorder (MCMD), remains prevalent in the HAART era, affecting an estimated 40% – 50% of HIV-infected individuals, while the more severe forms of dementia have been substantially reduced [4]. The occurrence of MCMD, despite the efficacy of HAART therapy in controlling the viral load, suggests that the CNS viral load is not the only factor determining the prevalence of HAND. In fact, some studies suggest that glial activation shows better correlation with the severity of HAND than the amount of HIV replication in brain [5,6].

Astrocytes are the most abundant cell type in the brain and play a primary role in the maintenance of homeostasis in the brain. They regulate synaptic transmission, maintain the integrity of the blood–brain barrier (BBB) and protect neurons by clearing toxic compounds [7]. HIV has been shown to produce restricted infection of astrocytes that can become productive in a supportive environment [8,9]. Upon HIV entry into the CNS, microglial cells, perivascular macrophages and astrocytes become activated and release a myriad of neurotoxins such as quinolinic acid, TGF-beta, TNF-α, MCP-1, RANTES/CCL5, IL-8, IP-10 and NO [10-15]. The HIV-infected cells in the CNS also release viral particles such as gp120 and Tat in the brain microenvironment. These viral particles have been demonstrated to elicit inflammatory responses from the glial cells and have also been implicated in neuronal apoptosis [16,17]. Given the abundance and importance of astrocytes in the CNS, their dysregulation could have profound and lasting consequences; for this reason, these cells are widely believed to be a major cell type involved in the progression of HAND. In fact, previous work from our laboratory has demonstrated a role for HIV-1 gp120 in the production of IL-6, IL-8 and CCL5 in astrocytes [18-20].

Viral protein R (Vpr) is a 96-amino-acid protein that is highly conserved among lentiviruses. The role of Vpr in HIV infection and replication is multifaceted and includes such functions as cell cycle arrest at the G2 phase, transport of the pre-integration complex into the nucleus and transactivation of HIV-1 long-terminal repeat [21-23]. The importance of Vpr in HIV pathogenesis is underscored by the findings that HIV infection in vitro is enhanced by Vpr [24,25]. Vpr has been found in the different brain cell types including astrocytes of HAND patients [26]. Some pathological changes associated with Vpr in the brain include neuronal apoptosis, impaired axonal growth, elevation of intracellular calcium and increased production of reactive oxygen species in neuronal cells [27-29]. Furthermore, Vpr was recently shown to induce IL-6 in monocyte-derived macrophages (MDM), which can reactivate virus production from latently infected cells [30].

CCL5, also known as RANTES, is a multifunctional chemokine with evidence available for both harmful and beneficial actions in the CNS. A study by Si et al. provided indirect evidence for the potential of Vpr to induce RANTES/CCL5 in human microglial cells, where Vpr deleted HIV-1 showed much lower levels of CCL5 when compared with intact HIV-1 containing Vpr [31]. Though the roles of Tat and gp120 have been extensively studied, little work has been done on the role of Vpr on the astrocytes. Given the potential role of Vpr in the activation of astrocytes and microglial cells, it seems likely that Vpr may play a critical role in the development of HAND. In view of this, we sought to address the direct effect of Vpr overexpression on the induction of chemokine RANTES/CCL5 in astrocytes. In this report, we also examined several distinct signaling mechanisms that contributed to the induction of CCL5 in astrocytes.

Materials and methods

Cell culture and reagents
SVGA, a clone of the human fetal astrocytic cell line (SVG) [32], was kindly provided by Dr. Avindra Nath. These cells were maintained in Dulbecco’s modified Eagle medium (DMEM, Cellgro) containing 10% FBS, 1% L-glutamine, 1% non-essential amino acids, 1% sodium bicarbonate and gentamycin (50 μg/ml) in a humidified incubator at 37°C and 5% CO₂. Lipofectamine™ 2000 was obtained from InVitrogen Inc. (Carlsbad, CA). Inhibitors for NF-κB (SC514: IKK-δ), P38/MAPK (SB203580), PI3K (LY294002) and JNK (SP600125) were obtained from Cayman Chemicals (Ann Arbor, MI, USA). Pre-designed siRNAs for NF-κB (p50, p65), p38-MAPK (p38α, p38β, p38γ, p38δ), Akt (Akt-1, Akt-2, Akt-3) and AP-1 were purchased from Thermo Fisher Scientific Inc. (Waltham, MA). All the experimental protocols used in this study were approved by the Institutional Biosafety Committee (IBC) at UMKC.

Construction of the HIV-1 Vpr plasmid
The Vpr expression plasmid was generated by amplification of the Vpr sequence from HIV-1 IIIB for cloning into the pcDNA3.1+ backbone. Briefly, H9/IIIB cells were cultured for RNA isolation. RNA was reverse transcribed and amplified by PCR using forward and reverse primers specific for the 5’ end (including the start codon) and 3’ end (including a stop codon) of the Vpr coding sequence, respectively. PCR product was verified by gel analysis and
cloned directionally into pcDNA3.1D TOPO cloning vector (Invitrogen). Clones were sequenced to assess codon integrity. The pcDNA3.1/Vpr96 clone was prepared for transfection by the Endo Free Plasmid Mega kit (Qiagen) using the standard protocol to obtain a high yield of endotoxin free plasmid.

Transfection
SVGA cells were transiently transfected with Lipofectamine™ 2000 as per the manufacturer’s protocol. Briefly, 0.8 × 10⁶ cells were incubated with 1 μg Vpr plasmid and 4 μl of lipofectamine in 1 ml serum-free medium for 5 h. The transfection was terminated by replacing the transfection medium with an equal volume of complete medium. The expression level of CCL5 was measured at 1, 3, 6, 12, 24, 48 and 72 h post transfection. For inhibition experiments, the cells were treated with 10 μM inhibitor (SB203580, LY294002, SP600125 and SC514) 1 h prior to the transfection with the plasmid encoding Vpr. For siRNA inhibition experiments, the cells were incubated for 24 h in transfection medium with 50 nmol of siRNA, followed by 24 h of incubation in complete medium before transfection with the plasmid encoding Vpr. For inhibitor and siRNA experiments, the mRNA expression level of CCL5 was determined at 6 h, while CCL5 protein levels were measured at 48 h post-transfection. Mock-transfected cells were used as a control to calculate the expression of CCL5.

Real-time RT-PCR and CCL5 protein determination
Total RNA was extracted from the SVGA cells using RNeasy mini kits (QIAGEN, Valencia, CA) using the manufacturer’s protocol. Then 150 ng of RNA was amplified using Bio-Rad iCycler using the primer sequences that were commercially synthesized. The primer sequences for CCL5 and PCR conditions used have been previously described [19]. HPRT (hypoxanthine-guanine phosphoribosyl transferase) was used as a housekeeping control, and the 2⁻ΔΔCt method was employed to calculate the expression levels of CCL5 [33]. The primer sequences and PCR conditions for p38 and Akt isoforms used in this study with slight modification have been previously described [34,35]. The annealing temperatures of the primers were selected based on their amplification in gradient PCR. The annealing temperatures in this study were 57.5°C (Akt-1, 2, 3 and p38δ), 58°C (p38α and p38γ) and 59.7°C (p38β) for 30 s.

The cell culture supernatants were centrifuged twice at 3,000 rpm and stored at −80°C. Centrifugation was done to remove the cell debris that has the potential to block the probe used in Bio-Plex system. The concentration of extracellularly secreted cytokines in the supernatants was measured by multiple cytokine assay kits (Bio-Rad, Hercules, CA) using the manufacturer’s protocol and previously published method [19]. The CCL5 concentration was determined based on 5PL standard curve using Bio-Plex manager 5.0 software.

Agarose gel electrophoresis
The PCR products for p38 and Akt isoforms were electrophoresed on 1.5% agarose gel for 1 h at 100 V. The gel was stained with 0.005% ethidium bromide and was visualized using the Alpha Innotech FluorChem™ imager for 8 ms under UV light.

Immunocytochemistry
On glass cover slips, 0.6 × 10⁶ cells were cultured in a six-well plate and transfected with the plasmid encoding Vpr. After 5 h, the transfection medium was replaced with complete DMEM containing 1 mg/ml GolgiStop™ (BD Biosciences, San Jose, CA) to prevent the release of CCL5. After 6 h, the cells were fixed with 1:1 ice-cold methanol:acetone for 20 min at 20°C. The cells were then permeabilized with PBST (PBS containing 0.1% TritonX-100) and blocked with 1% BSA in PBST for 30 min at room temperature. The cells were washed 5× with PBS after fixation and permeabilization. The cells were incubated with a mixture of a rabbit polyclonal antibody to CCL5 (1:500; P230E, Thermo Scientific, Rockford IL USA) and mouse MAb anti-GFAP (1:1,000; ab106509, Abcam) overnight in a humidified chamber. The cells were washed 5× with PBST and incubated with an anti-rabbit antibody conjugated with Alexa Fluor 488 (1:1,000; Cell Signaling Technology) and an anti-mouse antibody conjugated with Alexa Fluor 555 (1:1,000; Cell Signaling Technology) for 1 h at room temperature in the dark. All the antibodies were diluted in 1% BSA containing PBS. The cells were washed 5× with PBST and mounted on a glass slide with 10 μl of Vectashield mounting medium containing DAPI (Vector Laboratories, Burlingame, CA). The images were captured using Leica TCS SP5 II (Leica Microsystems, Wetzlar, Germany) on an inverted microscope platform with 40× zoom lens. The intensity of images was calculated using the Multi Measure tool from NIH ImageJ software. The values were normalized to GFAP.

Western blotting
SVGA astrocytes were either mock transfected or were transfected with a plasmid encoding HIV-1 Vpr, and the cells were harvested after 6 h, followed by the separation of nuclear and cytosolic extracts using the NE-PER nuclear extraction kit (Pierce, Rockford, IL). Total cell extracts were prepared by adding RIPA buffer (Boston Bioproducts, Ashland, MA). The lysates were homogenized for 15 s and centrifuged at 14,000 × g for 15 min to eliminate cell debris. Protein concentrations were determined using the BCA protein assay kit (Pierce, Rockford, IL), and 20 μg of protein was resolved on 10%
SDS-PAGE (75 V for 3 h). For immunoblotting, proteins were transferred (350 mA for 1.5 h) onto a PVDF membrane and blocked overnight at 4°C with 5% nonfat milk in PBST (PBS with 0.075% Tween 20). The membrane was incubated with primary antibodies against p50 (Santa Cruz Biotechnology Inc., 1:1,500) and c-fos (Cell Signaling Technology, 1:1,500) for 3 h at room temperature and washed 5× with PBST, followed by 2 h incubation in an appropriate concentration of secondary antibodies conjugated to horseradish peroxide. The membrane was then washed 5× with PBST, and the bands were visualized using the BM chemiluminescence Western blotting substrate (POD, Roche Applied Sciences; Indianapolis, IN). FluorChem HD2 software (Alpha Innotech, San Leandro, CA) was used for the quantification of the bands.

Statistical analysis
The results are expressed as mean ± SE for three independent experiments with each experiment done in triplicate. The statistical significance was calculated using Student’s t-test, and a p value ≤ 0.05 was considered significant.

Results
Time-dependent induction of CCL5 by HIV-1 Vpr in SVGA astrocytes
The expression levels of CCL5 are known to be increased in the CSF of individuals suffering from HAND. We transfected SVGA astrocytes with a plasmid encoding HIV-1 Vpr using Lipofectamine 2000 reagent to ascertain whether viral protein R has any role in increased CCL5 expression. The transfection efficiency as determined by GFP transfection followed by BD FACScanto flow cytometric analysis was in the range of 60-80% (data not shown). CCL5 mRNA expression was determined at 1, 3, 6, 12, 24, 48 and 72 h post-transfection (Figure 1A). The CCL5 mRNA expression level peaked at 3 (24.43 ± 3.18-fold) and declined thereafter to reach the basal level at 48 h. The increase in RNA level was further confirmed by determining the protein concentrations of CCL5 in cell culture supernatants. The supernatants were collected and analyzed at 6, 12, 24, 48 and 72 h after Vpr transfection of SVGA astrocytes (Figure 1B). We observed significantly higher levels of CCL5 in Vpr-transfected astrocytes compared to mock transfected at time as low as 6 h. The CCL5 protein concentration was higher at all time intervals analyzed, and the peak CCL5 concentration was seen at 48 h post-transfection (2,040.5 ± 209.6 pg/ml) compared to mock-transfected controls (200.7 ± 20.1 pg/ml).

Immunocytochemistry for HIV-1 Vpr-mediated induction of CCL5 in SVGA astrocytes
In order to further confirm HIV-1 Vpr-mediated increased expressions of CCL5, we performed immunocytochemistry on SVGA astrocytes after transfection with a plasmid encoding Vpr. The cells were immunostained with a cocktail of GFAP- and CCL5-specific antibodies. These proteins were visualized by staining with secondary antibodies conjugated to Alexa Fluor 488 (green) and Alexa Fluor 555 (red) for CCL5 and GFAP, respectively. DAPI staining was used to visualize the nuclei of the cells. A representative staining is shown in Figure 2. A strong yellow signal in the merged images signifying the accumulation of CCL5 that was co-localized with GFAP was seen in the astrocytes transfected with Vpr (Figure 2G-I) as compared to mock-transfected (Figure 2D-F) or untransfected controls (Figure 2A-C). Our results also indicated that mock transfection caused a slight but statistically non-significant decrease in CCL5 expression (Figure 2J). On the other hand, relative CCL5 expression in HIV-1 Vpr-transfected cells was 2.4- and 3.1-fold higher
compared to control and mock-transfected cells, respectively (Figure 2).

**HIV-1 Vpr-mediated upregulation of CCL5 was abrogated with inhibitor and siRNA against the NF-κB pathway**

To identify the role of NF-κB in HIV-1 Vpr-mediated upregulation of CCL5 in astrocytes, we tested SC514, which is a specific inhibitor of NF-κB activation. The concentration of inhibitor used was determined based on IC50 values and its effect on cell viability (data not shown). The cells were pre-treated 1 h with 10 μM of SC514 before Vpr transfection, and the inhibitor was present throughout the experiment. The CCL5 mRNA expression and protein concentration were measured at 6 and 48 h post transfection, respectively (Figure 3A, B). SC514 treatment significantly inhibited the production of CCL5 at mRNA (8.85 ± 0.64-fold) and protein level (1,681.9 ± 65.6 pg/ml) as compared to untreated controls (13.15 ± 0.54-fold, 2,471.6 ± 110.9 pg/ml). To further confirm the role of NF-κB, we transfected the cells with siRNA against p50 and p65 subunits of NF-κB for 48 h before transfecting them with a plasmid encoding Vpr (Figure 3C, D). HIV-1 Vpr caused reduced CCL5 mRNA expression in both p50 siRNA (2.4 ± 0.43-fold) and p65 siRNA (3.49 ± 0.61-fold) transfected cells as compared to those cells transfected with scrambled siRNA (8.11 ± 1.82-fold). We observed similar trend in the CCL5 protein levels as well with p50 siRNA (540.42 ± 41.39 pg/ml) and p65 siRNA (864.32 ± 77.43 pg/ml) showing statistically significant reductions as compared to scrambled siRNA transfected control (2,417.36 ± 553.39 pg/ml).

**Involvement of the p38-MAPK and AP-1 pathway in HIV-1 Vpr-mediated induction of CCL5 in astrocytes**

To dissect the upstream pathway involved in the production of CCL5 after Vpr transfection of SVGA astrocytes, we tested the chemical inhibitors for the MAPK (SP600125-JNK, SB203580-p38) pathway. The optimum concentration of inhibitor was determined based on cell viability and dose–response studies (data not shown). The cells were pre-treated for 1 h with 10 μM of inhibitors and then were either mock transfected or transfected with a plasmid encoding Vpr. No significant reductions (Figure 4A, B) were seen with either SP600125 (13.89 ± 0.85-fold, 2,919.9 ± 111.5 pg/ml) or SB203580 (22.89 ± 2.09-fold, 4,233.6 ± 433.3 pg/ml) as compared to untreated controls (13.99 ± 1.65-fold, 2,946.92 ± 639.9 pg/ml). For confirmation, SVGA cells were transfected with siRNA against p38-MAPK (α, β, γ and δ) isoforms (Figure 4C, D). Surprisingly, siRNA against the p38δ isoform showed inhibition at both the mRNA (4.11 ± 0.42-fold) and protein (1,298.2 ± 40.96 pg/ml) levels, which was not seen with chemical inhibitor against the p38 pathway. This was in confirmation of a previous report that SB203580 inhibits only the α and β but not the γ and δ isoforms of the p38 pathway [36]. In order to determine the specific silencing effect of individual p38 isoform-specific siRNA, we amplified the RNA from the cells depleted with different p38 isoforms. The knockdown of the target was assessed by resolving the product on agarose gel (Figure 4E) with HPRT as a housekeeping control. To ascertain the downstream signaling molecule of p38 δ MAPK, we transfected the cells with siRNA against AP-1 transcription factor and determined the effect of Vpr transfection at 6 h for mRNA and 48 h for protein expression (Figure 4F, G). Statistically significant reduction was seen with siRNA directed against AP-1 at mRNA (4.43 ± 0.62-fold) and protein (1,598.34 ± 104.9 pg/ml) levels. This was further confirmed by determining the levels of c-fos, one of the major subunits of AP-1, after the transfection with p38δ-specific siRNA.
The transfection of HIV-1 Vpr in astrocytes led to an increase in the levels of c-fos, which was partially reversed by p38δ-specific siRNA but not with scrambled siRNA.

**PI3K/Akt-mediated activation of NF-κB plays a role in the HIV-1 Vpr-mediated expression of CCL5 in SVGA astrocytes**

To understand the upstream signaling responsible for the activation of NF-κB in HIV-1 Vpr-mediated induction of CCL5 in astrocytes, we pre-treated the cells with the PI3K/Akt inhibitor LY294002 (10 μM). The optimal dose concentration was determined based on the dose–response and cell viability studies. Pre-treatment with LY294002 (Figure 5A, B) substantially reduced the expression of CCL5 (9.02 ± 1.30-fold; 1,188.8 ± 343.1 pg/ml) as compared to untreated controls (13.99 ± 1.65-fold, 2,946.9 ± 639.9 pg/ml) after transfection of astrocytes with HIV-1 Vpr. Further, to corroborate the inhibition seen with LY294002, we transfected Vpr into the cells that were already transfected with siRNA against Akt isoforms (Akt-1, Akt-2 and Akt-3) or scrambled control (Figure 5C, D). The astrocytes transfected with siRNAs that targeted Akt-2 (3.83 ± 0.64-fold; 1,742.8 ± 82.6 pg/ml) and Akt-3 (3.54 ± 0.53-fold; 1,408.2 ± 150.8 pg/ml) showed significant abrogation of CCL5 at both the mRNA and protein levels as compared to scrambled siRNA-transfected control (6.26 ± 0.31-fold, 2,158.9 ± 257.5 pg/ml) after Vpr transfection. The slight inhibition seen with Akt-1 isoform (5.69 ± 0.38-fold; 1,846.3 ± 274.1 pg/ml) was not statistically significant. Specificity of the siRNAs for Akt isoforms was determined by amplifying the silenced RNA using Akt isoform-specific primers. The products were then resolved on the agarose gel, stained with ethidium bromide and visualized under UV light (Figure 5E). Amplification of HPRT was used as a housekeeping control.

To confirm whether PI3K/Akt signaling is involved in the activation NF-κB, LY294002-treated cells were analyzed for the translocation of p50 from cytosol to nucleus. PI3K/Akt inhibition by LY294002 substantially reduced p50 translocation as compared to inhibitor-untreated controls (Figure 5F). This clearly demonstrates that NF-κB activation in response to HIV-1 Vpr was mediated though PI3K/Akt signaling. The schematic representation (Figure 6) depicts that HIV-1 Vpr induces the expression of CCL5 in astrocytes through the activation of transcription factors.

---

**Figure 3** Involvement of NF-κB in HIV-1 Vpr-mediated upregulation of CCL5 in astrocytes. SVGA astrocytes were pre-treated with the chemical inhibitors or transfected with siRNA targeting the NF-κB pathway, followed by mock transfection or transfection with a plasmid encoding Vpr. (A) and (B) Effect of chemical inhibitor of the NF-κB pathway, SC514 on mRNA expression and protein concentration for CCL5, respectively. (C) and (D) Effect of siRNA against p50 and p65 subunits of NF-κB on CCL5 mRNA expression and protein concentration, respectively. The bars represent the mean ± SE of three independent experiments done in triplicate. Statistical significance was determined using Student’s t-test, **p < 0.01, *p < 0.05.
Figure 4 (See legend on next page.)
In T-cells, CCL5 has been shown to be present in inflammatory as opposed to the neuroprotective scenario. Astrocytes, which might be closely related to neuroblastoma cells [45]. We found a CCL5 concentration of shown that 50 ng/ml CCL5 induces apoptosis in neuronal cells [42,43]. Also CCL5 treatment of the differentiated neuronal cell line at 300 ng/ml has been shown to protect the neuronal cells from HIV-1 gp120-mediated cell death [42,43]. Also CCL5 treatment of the differentiated neuronal cell line at 300 ng/ml has been shown to be present in unique storage vesicles and rapidly released after T-cell activation [46]. However, in our experimental conditions, CCL5 was observed to be secretory soon after production as we detected significant concentration of CCL5 within 6 h. Therefore, It seems that the CCL5 storage phenomenon in distinct secretory compartments may be cell-type specific.

NF-κB is a ubiquitous transcription factor, involved in the regulation of myriad of inflammatory genes as well as cell survival signaling pathways. It plays an essential role in the expression of the CCL5 gene as well [47]. To explore the possibility of involvement of NF-κB in CCL5 induction by HIV-1 Vpr in astrocytes, we employed SC514, which is a specific inhibitor for the IKK-2 pathway of NF-κB activation [48]. IKKs are upstream kinases responsible for phosphorylation and proteasomal degradation of IκB-α and subsequent activation of NF-κB. NF-κB complex consists of p50 and p65 subunits attached to inhibitory IκB-α, which retains them in the cytosol. This complex gets activated by the removal of IκB-α, translocates to the nucleus and binds to the promoter regions of specific genes [49]. The reduction in CCL5 expression by SC514 therefore confirms the involvement of the NF-κB pathway in HIV-1 Vpr-mediated production of CCL5 in astrocytes. Our results using p50- and p65-specific siRNA also demonstrate the direct involvement of NF-κB in CCL5 expression.

Recently, it has been reported that CCL5 expression in astrocytes can be blocked by the inhibitors of the MAPK and PI3K pathway [50]. The CCL5 promoter contains binding sites not only for NF-κB, but also for CREB (cAMP response element-binding protein), AP-1 (activator protein 1), C/EBP (CCAAT/enhancer binding protein) and IRF (interferon regulatory factor) [51]. These transcription factors are known to involve upstream signaling through the MAPK and PI3K/Akt pathway. In this study, the treatment of astrocytes with LY294002 (PI3K/Akt) but not with SB203580 (p38 MAPK) and SP600125 (JNK/MAPK) inhibited the CCL5 expression in response to HIV-1 Vpr. These results clearly suggest that PI3K/Akt but not JNK/MAPK is involved in NF-κB activation in our system. In our attempt to further dissect the involvement of PI3K/Akt, we employed Akt-specific siRNAs. Akt, also known as protein kinase B, is...
a family of serine/threonine kinases comprising three isoforms, Akt-1, Akt-2 and Akt-3. They differ from each other in only one amino acid residue in their phosphorylation/activation site, Akt-1 (ser-473, thr-308), Akt-2 (ser-474, thr-309) and Akt-3 (ser-472, thr-305) [52]. They also differ in their subcellular localization in a tissue-specific manner, with Akt-3 being the most abundant isoform in the brain [52,53]. It has been shown that Akt-3-deficient mice have smaller brains with suppressed inflammatory responses in experimental autoimmune encephalomyelitis.
Recently, Akt-2 deficient macrophages have been shown to be hyporesponsive to LPS and produce lower levels of IL-6 and TNF-α [53]. In our study, siRNA mediated knockdown of Akt-2 and Akt-3 isoforms but not Akt-1 showed suppression of CCL5, which is in consistent with earlier reports that Akt-2 and Akt-3 play an important role in regulation of cytokine gene expression [54,55].

Our results showing only partial abrogation of CCL5 expression by SC514, LY294002, sip50 and sip65 suggest the possibility that other signaling mechanisms are also involved in HIV-1 Vpr-mediated CCL5 upregulation. Therefore, we explored various p38 MAP kinases. There are four isoforms of the p38-MAPK pathway, p38α, p38β, p38γ and p38δ, which can be activated by stress and are distributed in a tissue-specific manner. SB203580 (a p38 chemical inhibitor) did not show any CCL5 inhibition, but it is a known inhibitor of only p38α and p38β isoforms with no or minimal inhibition at higher concentrations on p38γ and p38δ isoforms [36]. We therefore used siRNAs against each p38 isoform. Our results with p38δ siRNA raised the possibility of involvement of another transcription factor (AP-1) because the CCL5 promoter contains an AP-1 responsive element and has been shown to be involved in the production of CCL5 [47]. This was confirmed by siRNA-mediated AP-1 knockdown. The p38δ and AP-1 connection has been shown in other systems as well, as it has been shown to regulate keratinocyte differentiation through the AP-1 transcription factor [56].

Furthermore, synthetic Vpr protein has been shown to activate AP-1, which in turn stimulates HIV-1 transcription in monocytes and macrophages [57]. We also found the reduction in the expression of c-fos subunit of AP-1 with the siRNA directed against p38δ. This clearly demonstrates the involvement of AP-1 in HIV-1 Vpr-mediated induction of CCL5 in astrocytes. Further, the activation and nuclear translocation of the p50 subunit of NF-κB involved PI3K/Akt signaling were illustrated with the reduction of p50 nuclear levels in the presence of LY294002. This provides direct evidence for the involvement of PI3K/Akt in the activation of NF-κB with the transfection of astrocytes with HIV-1 Vpr. Our studies are in accordance with the previous report suggesting the involvement of HIV-1 Vpr in the activation of transcription factors such as NF-κB and AP-1 in primary macrophages [57].

Conclusions

In summary, we have shown that HIV-1 Vpr induces CCL5 expression in astrocytes in a time-dependent manner. Furthermore, CCL5 expression involved the transcription factors NF-κB and AP-1. AP-1 was shown to be activated by p38δ, while NF-κB activation involved signaling through the PI3K/Akt pathway (Figure 6). These studies are important for the development of adjunct therapy as we have identified different steps that could be targeted to suppress CCL5 expression.
Competing interest
The authors declare that they have no competing interests.

Authors' contributions
MG executed most of the experiments and analyzed the data shown in this manuscript. He also wrote the first draft of the manuscript. RN constructed HIV-1 Vpr plasmid. AS helped MG to learn some of the techniques used for this project. VRA participated in the project design. AK conceptualized the project and finalized the manuscript. All the authors have read and approved the final version of the manuscript.

Acknowledgements
The authors thank Dr. Peter Silverstein for critical reading of the manuscript. This work was supported by grants from National Institute on Drug Abuse (DA025526 and DA 025011). We also acknowledge the use of the confocal microscope at the University of Missouri, Kansas City School of Dentistry Confocal Microscopy Core (supported by NIH grant S10RR027668).

Author details
1Division of Pharmacology and Toxicology, School of Pharmacy, University of Missouri, Kansas City, MO 64108, USA.
2Departments of Biochemistry, Ponce School of Medicine and Health Sciences, Ponce, PR 00716, USA.
3Departments of Microbiology, Ponce School of Medicine and Health Sciences, Ponce, PR 00716, USA.

Received: 27 July 2013 Accepted: 28 October 2013

Published: 13 November 2013

References
1. Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, Yungbluth M, Janotta F, Aksamit A, Martin MA, Fauci AS: Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 1986, 233:1768-1769.
2. Vazquez R, Brousse N, Jarry A, Henin D, Marche C, Vedrenne C, Mikol J, Wolff M, Michon C, Rozenbaum W, et al: AIDS subacute encephalitis: identification of HIV-infected cells. Am J Pathol 1987, 126(1):403-405.
3. Valcuor V, Chalmers RA, Saistosa N, Marovich M, Lerd limb S, Suttichom D, Suwanwela NC, Jagodinski L, Michael N, Spudich S, et al:Central nervous system viral inflammation and infection during acute HIV infection. J Infect Dis 2012, 206(1):275-284.
4. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Hawkins BJ, Brailoiu E, Cohen E, Power C, Brailoiu E, Berman J, Power C, Brailoiu E, Berman J: HIV-1 Vpr transactivates LTR-directed expression through a nuclear factor-kappa B-dependent mechanism: suppression by gp120 specific small interfering RNA. PLoS One 2011, 6(6):e21261.
5. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR: Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 1995, 69(11):6705-6711.
6. Heinzinger NK, Bukinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Lee MA, Gendelman HE, Ratner L, Stevenson M, Emremman M: The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 1994, 91(15):7311-7315.
7. Vanitharani R, Mahalingam S, Rafaiei Y, Singh SP, Srinivasan A, Weiner DB, Ayyavoo V: HIV-1 Vpr transactivates LTR-directed expression through sequences present within –278 to –176 and increases virus replication in vitro. Virology 2001, 289:342-344.
8. Ayyavoo V, Mahalingam S, Rafaiei Y, Kudchodkar S, Chang D, Nagashanmugum T, Williams WW, Weiner DB: HIV-1 viral protein R (Vpr) regulates viral replication and cellular proliferation in T cells and monocyteid cells in vitro. Journal of leukocyte biology 1997, 62(1):99-109.
9. Levy DN, Rafaiei Y, Weiner DB: Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. Journal of virology 1995, 69(2):1243-1252.
10. Mukerjee R, Chang Jr, Bonfanti Z, Bagashe M, Gayed MM, Lysy RB, Hawkins BJS, Braiolo E, Cohen E, Passo C, et al: Deregulation of microRNAs by HIV-1 Vpr protein leads to the development of neurocognitive disorders. J Biol Chem 2011, 286(40):34976-34985.
11. Levy DN, Rafaiei Y, Weiner DB: Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J Biol Chem 2011, 286(40):34976-34985.
12. Rom I, Heidman SL, Mukerjee R, Khali M, Amin S, Sawaya BE: HIV-1 Vpr regulates calcium secretion in neural cells. Brain Res 2009, 1275:81-86.
13. Hoshino S, Konishi M, Mori M, Shimura M, Nishitani C, Kuroki Y, Koyanagi Y, Kano S, Itabe H, Ishizaka Y: HIV-1 Vpr induces TL4/MYD88-mediated IL-6 production and reactivates viral production from latency. J Leucoc Biol 2010, 87(6):1133-1143.
14. Hoshino S, Oumi Y, Koyanagi I, Konishi M, Mori M, Shimura M, Nishitani C, Kuroki Y, Amin S, Itabe H, Ishizaka Y: HIV-1 Vpr induces TL4/MYD88-mediated IL-6 production and reactivates viral production from latency. J Leucoc Biol 2010, 87(6):1133-1143.
15. Kondo K, Kim MO, Zhao ML, Landau NR, Goldstein H, Lee S: Vpr- and Nef-dependent induction of RANTES/CCL5 in microglial cells. Virology 2002, 301(2):342-353.
32. Major EO, Miller AE, Mournian P, Traub RG, de Witte E, Sever J: Establishment of a line of human fetal glial cells that supports JC virus multiplication. Proc Natl Acad Sci USA 1985, 82(4):1257–1261.

33. Schmitgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3(11):1101–1108.

34. Uddin S, Ah-Kang J, Ulaszek J, Mahmud D, Wickrema A: Differential stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. Proc Natl Acad Sci USA 2004, 101(11):147–152.

35. Fillmore GC, Wang Q, Carey MJ, Elenton-Johnson KS, Lim MS: Expression of Akt (protein kinase B) and its isoforms in malignant lymphomas. Leuk Lymphoma 2005, 46(12):1765–1773.

36. Lee JC, Kassis S, Kumar S, Badger A, Adams JL: p38 mitogen-activated protein kinase inhibitors—mechanisms and therapeutic potentials. Pharmacol Ther 1999, 82(2–3):389–397.

37. Muthumali K, Hwang DS, Desai BM, Zhang D, Days N, Green DR, Weiner DB: HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J Biol Chem 2002, 277(30):27820–27831.

38. Patel CA, Mukhtar M, Pomerantz RJ: Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells. J Virol 2000, 74(20):9717–9726.

39. Noorbakhsh F, Ramachandran R, Barsby N, Ellestad KK, LeBlanc A, Dickie P, Spano P: Gene expression profile activated by the chemokine CCLS/RANTES in human neuronal cells. J Neurosci Res 2004, 78(3):371–382.

40. Wickremasinghe MI, Thomas LH, O’Kane CM, Uddin J, Friedland JS: Analyzing real-time PCR data by the comparative \( C(T) \) method. J Virol 2002, 76(1):465–466.

41. Gordon CJ, Muesing MA, Proudfoot AE, Power CA, Moore JP, Trkola A: Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion. J Virol 1999, 73(6):684–694.

42. Meucci O, Fatatis A, Simen AA, Bushell TJ, Gray PW, Miller RJ: Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci USA 1998, 95(24):14500–14505.

43. Kaul M, Lipton SA: Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci USA 1999, 96(16):8212–8216.

44. Valerio A, Ferrario M, Martinez FO, Locati M, Ghisi V, Bresciani LG, Mantovani A, Spano P: Gene expression profile activated by the chemokine CCLS/RANTES in human neuronal cells. J Neurosci Res 2004, 78(3):371–382.

45. Cartier L, Dubois-Dauphin M, Hartley O, Irminger-Finger I, Krause KH: Chemokine-induced cell death in CCR5-expressing neuroblastoma cells. J Neuroimmunol 2003, 145(1–2):27–39.

46. Catalfaro M, Karpova T, McNally J, Costes SV, Lockett SJ, Bos E, Peters PJ, Henkart PA: Human CD8+ T cells store RANTES in a unique secretory compartment and release it rapidly after TcR stimulation. Immunity 2004, 20(2):219–230.

47. Wickramesinghe MI, Thomas LH, O’Kane CM, Uddin J, Friedland JS: Transcriptional mechanisms regulating alveolar epithelial cell-specific CCLS secretion in pulmonary tuberculosis. J Biol Chem 2004, 279(20):27199–27205.

48. Kishore N, Sommers C, Mathialagan S, Guzova J, Yao M, Hauser S, Huyhn K, Bonar S, Mielke C, Albee L, et al: A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts. J Biol Chem 2003, 278(35):32681–32687.

49. Oelkinghaus A, Hayden MS, Ghosh S: Crossstalk in NF-kappaB signaling pathways. Nat Immunol 2011, 12(8):695–708.

50. Lin MS, Hung KS, Chiu WT, Sun YY, Tsai SH, Lin JW, Lee YH: Curcumin enhances neuronal survival in N-methyl-d-aspartic acid toxicity by inducing RANTES expression in astrocytes via PI-3 K and MAPK signaling pathways. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(4):931–938.

51. Casola A, Garofalo RF, Haerebe H, Elliott TF, Lin R, Jamulaudin M, Brasier AR: Multiple cis regulatory elements control RANTES promoter activity in alveolar epithelial cells infected with respiratory syncytial virus. J Virol 2001, 75(14):6428–6439.

52. Santi SA, Lee H: The Akt isoforms are present at distinct subcellular locations. Am J Physiol Cell Physiol 2010, 298(3):C580–C591.

53. Easton RM, Choi H, Roovers K, Shinneman DW, Mizani M, Forman MS, Lee VM, Szabolcs M, de Jong R, Ottersdorf T, et al: Role for Akt3/protein kinase B gamma in attainment of normal brain size. Mol Cell Biol 2005, 25(9):1869–1878.

54. Tsiperson V, Gruber RC, Goldberg MF, Jordan A, Weinger JG, Macian F, Shaftz-Zagardo B: Suppression of inflammatory responses during myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis is regulated by AKT3 signaling. J Immunol 2013, 190(4):1528–1539.

55. Arranz A, Dovak C, Vergadi E, de la Torre MY, Vapordi K, Lagoudakis ED, Ieronymaki E, Androulidaki A, Vyneni H, Margioris AN, et al: Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization. Proc Natl Acad Sci USA 2012, 109(24):9517–9522.

56. Eckert RL, Adhikary G, Young CA, Jans R, Crish JF, Xu W, Roeke EA: AP1 transcription factors in epidermal differentiation and skin cancer. J Skin Cancer 2013, 2013:573028.

57. Varín A, Decresci AZ, Sabha B, Quivy V, Sie J, Van Lint C, Roques BP, Aggarwal BB, Herbin G: Synthetic Vpr protein activates activator protein-1, c-Jun N-terminal kinase, and NF-kappa B and stimulates HIV-1 transcription in promonocytic cells and primary macrophages. J Biol Chem 2005, 280(52):42557–42567.

Cite this article as: Gangwani et al.: Human immunodeficiency virus type 1 viral protein R (Vpr) induces CCLS expression in astrocytes via PI3K and MAPK signaling pathways. Journal of Neuroinflammation 2013 10:136.